Pure Bioscience, INC

PURE Bioscience announced fiscal third quarter 2026 financial results, showing increased net product sales and a reduced net loss for the nine-month period, alongside a significant leadership transition.

PURE Bioscience, Inc. has secured $1.0 million in a private placement financing through the issuance of 18,131,096 shares of common stock.

PURE Bioscience, Inc. announced fiscal first quarter 2026 financial results, reporting increased net product sales and a reduced net loss.

PURE Bioscience, Inc. announced key leadership promotions, appointing Jeffrey Kitchell as President and Dolana Blount as Vice President of Operations, effective November 17, 2025.

PURE Bioscience, Inc. announced improved financial results for fiscal year 2025, driven by increased sales and reduced operating expenses, alongside strategic expansion into new markets.

PURE Bioscience, Inc. announced its fiscal third quarter 2025 financial results, showing increased net product sales and a reduced net loss for the quarter, alongside the successful demonstration of its SDC technology in commercial dairy plants.

PURE Bioscience reports increased net product sales for Q3 2026 compared to the prior year, though the company continues to operate at a net loss and faces going concern uncertainties.

PURE Bioscience, Inc. reported increased net product sales and reduced operating loss for the first fiscal quarter ended October 31, 2025, yet continues to face substantial doubt regarding its ability to continue as a going concern.

PURE Bioscience, Inc. filed its quarterly report, revealing ongoing net losses and a significant stockholders' deficiency, raising substantial doubt about its ability to continue as a going concern, despite increased revenue in the recent quarter and new convertible note financing from related parties.

PURE Bioscience reports a net loss of $1.487 million on net revenue of $947,000 for the six months ended January 31, 2025, raising substantial doubt about its ability to continue as a going concern.

PURE Bioscience reported a decrease in net product sales and a net loss for the first quarter of fiscal year 2025, while also raising additional capital through convertible notes.

PURE Bioscience reported increased revenue and gross margins for the third quarter of 2024, but continues to face challenges with ongoing losses and liquidity concerns.

PURE Bioscience, Inc. reported a net loss of $2.4 million for fiscal year 2025, despite a slight increase in net product sales, and continues to rely on convertible debt financing from related parties.

PURE Bioscience's annual report reveals a net loss of $3.4 million for fiscal year 2024 and raises concerns about the company's ability to continue as a going concern.

Thomas Myers, Exec VP of Tech & Development at Pure Bioscience, acquired 155,000 stock options on August 20, 2024.

Director David Rendall reports acquisition of stock options in Pure Bioscience, Inc.

Director Bernard Blotner acquired stock options in PURE Bioscience, Inc. on August 20, 2024.

Mark Stuart Elliott, Vice President of Finance at Pure Bioscience, acquired stock options for 155,000 shares at an exercise price of $0.07 on August 20, 2024.

Director Tom Y. Lee acquired stock options in PURE Bioscience, Inc. on August 20, 2024.

Robert Bartlett, CEO and President of Pure Bioscience, acquired options to purchase company stock on August 20, 2024.

PURE Bioscience, Inc. will hold its 2026 Annual Meeting to vote on director elections, auditor ratification, executive compensation, and a proposal to increase authorized common stock from 200 million to 250 million shares.

PURE Bioscience has announced its 2025 annual meeting of stockholders to be held on January 22, 2025, to vote on the election of directors, ratification of auditors, and executive compensation.